- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00821561
A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
February 24, 2010 updated by: OcuNexus Therapeutics, Inc.
A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon® in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with Persistent Epithelial Defects (PED) originally caused by chemical burns.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
90
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects aged 18 years and over.
- Subjects who are able to attend all follow-up visits and who are able to comply with all study procedures.
- Subjects who are willing and able to give written informed consent to take part in the study.
- At the Day -7 visit subjects must have a corneal epithelial defect that has persisted for between 7 days and 14 days, which has a minimum diameter of 2 mm along the greatest axis, and which has not shown improvement despite conventional treatment such as tear supplements and bandage contact lenses.
- The original defect to the cornea must have been caused by either alkaline or acidic agents.
Exclusion Criteria:
- Use of concomitant ocular medications in the screening period that are not specified in standardized PED treatment regime
- Likely to require the use of concomitant ocular medications that are not specified in the standardized PED treatment regime during the study follow-up period
- Decrease or increase in the PED by more than 30% during the screening period.
- Have an active lid or ocular infectious process of any sort
- Subjects with corneal perforation or impending corneal perforation
- The circumference affected by limbal blood vessel ischemia is greater than 75% of the circumference
- Subjects with severe lid abnormalities contributory to the persistence of the PED such as inability to close the lids.
- Subjects with bilateral PED, if the smaller PED has a longest diameter of > 2 mm.
- Female subjects who are pregnant or breastfeeding. F
- Subjects who have a history of AIDS or HIV.
- Subjects with any other condition which, in the Investigator's opinion, would exclude the subject from participating.
- Treatment with systemic corticosteroids (equivalent to > 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents within 7 days prior to Day 0, or likely to receive one of these therapies during study participation
- Subjects who have participated in a clinical trial within 30 days prior to Day 0.
- Diabetics with an HbA1c greater than 6.5%.
- Diabetics who are currently prescribed more than one oral medication for their diabetes.
- Subjects who have more than one distinct PED in the study eye.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary objective of this study is to evaluate the efficacy and safety of Nexagon® as a treatment for PED from chemical burn injuries.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (ANTICIPATED)
November 1, 2009
Study Completion (ANTICIPATED)
March 1, 2010
Study Registration Dates
First Submitted
January 10, 2009
First Submitted That Met QC Criteria
January 12, 2009
First Posted (ESTIMATE)
January 13, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
February 26, 2010
Last Update Submitted That Met QC Criteria
February 24, 2010
Last Verified
February 1, 2010
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NEX-PED-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Persistent Epithelial Defect
-
Universidad Autonoma de Nuevo LeonHospital Universitario Dr. Jose E. GonzalezRecruitingPersistent Epithelial DefectMexico
-
Hanan JafarCompletedPersistent Corneal Epithelial DefectJordan
-
Amber Ophthalmics, Inc.RecruitingPersistent Corneal Epithelial DefectUnited States
-
Noveome Biotherapeutics, formerly StemnionIQVIA BiotechTerminatedPersistent Corneal Epithelial DefectUnited States
-
Santen Pharmaceutical Co., Ltd.CompletedPersistent Corneal Epithelial DefectJapan
-
Combangio, IncKala Pharmaceuticals, Inc.RecruitingPersistent Corneal Epithelial DefectUnited States
-
Amber Ophthalmics, Inc.RecruitingCorneal Persistent Epithelial DefectUnited States
-
Kiora Pharmaceuticals, Inc.CompletedPersistent Corneal Epithelial DefectMexico
-
Noveome Biotherapeutics, formerly StemnionCompletedPersistent Corneal Epithelial DefectUnited States
-
TBF Genie TissulaireWithdrawnCorneal Ulcer | Persistent Corneal Epithelial Defect
Clinical Trials on Nexagon®
-
OcuNexus Therapeutics, Inc.CompletedVenous UlcerNew Zealand, United States
-
OcuNexus Therapeutics, Inc.CompletedDiabetic Foot UlcersRussian Federation, United States, Ukraine
-
OcuNexus Therapeutics, Inc.TerminatedDiabetic Foot UlcerNew Zealand
-
OcuNexus Therapeutics, Inc.CompletedVenous Leg UlcersUnited States, New Zealand, South Africa, Australia
-
Amber Ophthalmics, Inc.RecruitingCorneal Persistent Epithelial DefectUnited States
-
Amber Ophthalmics, Inc.RecruitingPersistent Corneal Epithelial DefectUnited States
-
OcuNexus Therapeutics, Inc.CompletedCorneal re-EpithelializationNew Zealand
-
OcuNexus Therapeutics, Inc.Completed
-
The Cleveland ClinicNovartisCompleted
-
University of California, San FranciscoFDA Office of Orphan Products DevelopmentTerminatedPersistent Corneal Epithelial Defects